Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Length of the endometrial cavity as measured by uterine sounding and ultrasonography in women of different parities

Full text
Author(s):
Canteiro, Renata [1] ; Bahamondes, M. Valeria [1] ; Fernandes, Arlete dos Santos [1] ; Espejo-Arce, Ximena [1] ; Marchi, Nadia M. [1] ; Bahamondes, Luis [1]
Total Authors: 6
Affiliation:
[1] Univ Estadual Campinas, Natl Inst Hormones & Womens Hlth, BR-13084971 Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Contraception; v. 81, n. 6, p. 515-519, JUN 2010.
Web of Science Citations: 19
Abstract

Background: In view of current controversies regarding the need for new, shorter intrauterine devices (IUDs) that would reduce expulsion rates in nulligravida, endometrial cavity length was measured in women of different parities using uterine sounding and ultrasonography. Study Design: A cross-sectional descriptive study was performed including 570 women of 17-52 years of age, 260 of whom were nulligravida and 310 parous. Results: The difference in mean length between measurements taken by uterine sounding and ultrasonography was 0.28 cm. Mean endometrial cavity length was 3.84 +/- 0.03 cm (mean +/- S.E.M.) in nulligravida and 4.25 +/- 0.03 cm in parous women according to uterine sounding (p<.001) and 3.70 +/- 0.03 cm and 3.84 +/- 0.03 cm, respectively, according to ultrasonography (p=.006). Conclusions: By either technique, mean length of the endometrial cavity was >3.6 cm, the length of the most common IUDs, the TCu380A and the levonorgestrel-releasing intrauterine system. Therefore, the issue appears controversial for developing new, shorter IUDs, since current models fit most women, including nulligravida, albeit one third of the women of our sample showed endometrial length shorter than 3.2 cm. (C) 2010 Elsevier Inc. All rights reserved (AU)

FAPESP's process: 03/08391-7 - Evaluation of the clinical and molecular repercussions of the use of contraceptives that contain only progestogen
Grantee:Luis Guillermo Bahamondes
Support Opportunities: Research Projects - Thematic Grants